

**NEVADA DEPARTMENT OF CORRECTIONS**

**EXECUTION MANUAL**

**EM 103**

**ACQUISITION AND PREPARATION OF DRUGS FOR LETHAL**

**INJECTION**

**Effective Date:**      **06/11/2018**

**CONFIDENTIAL IN UN-REDACTED FORMAT: NO**

**AUTHORITY AND RESPONSIBILITY**

The Director and designated Deputy Director will ensure that this manual is accurately revised and published upon order of the Governor prior to a scheduled execution.

**103.01            LETHAL INJECTION PROTOCOL**

- A. Lethal drugs are to be used in the execution. Although the combination of drugs and doses listed below are lethal for most individuals, individual differences do exist. It shall be the responsibility of the Director to consult with the Chief Medical Officer in order to ensure that the selected lethal drug or combination of drugs and their dosages to be used in the execution are sufficient to cause death. The Director shall then select the drug, combination of drugs and dosages to be used for the execution. This information will not be withheld from the inmate or the public.
  1. The NDOC Public Information Officer (PIO) will prepare and produce a statement on behalf of the Nevada Department of Corrections.
- B. The Director will provide the condemned inmate with written notice of the drug or combination of drugs that will be used for the execution after a final decision has been made and no less than seven (7) calendar days prior to the first day of the week (i.e. Monday), as designated by the district court, that the judgment of death is to be executed.
  1. If at any time after written notice of the drug or combination of drugs to be used for the execution has been provided to the condemned inmate, the Director determines that it is necessary to change the Lethal Injection Protocol identified and provided in CEM 110.02, a written notice of the Director's determination, which identifies the necessary changes to the Lethal Injection Protocol and an explanation as to the basis for such changes, will be immediately provided to both the condemned inmate and the condemned inmate's counsel of record.
- C. The drug amounts specified below are designed for the execution of persons weighing 500 pounds or less. The drug amounts will be reviewed and revised, as necessary, for a condemned inmate exceeding 500 pounds.

## **103.02 ACQUIRING LETHAL DRUGS AND EQUIPMENT**

- A. After the Director makes the final decision as to the drug or combination of drugs that will be used for the scheduled execution, the designated Deputy Director/designated Warden will be responsible for:
1. Confirming that the equipment and materials necessary to properly conduct the execution is on site, immediately available for use and functioning properly.
  2. Ensuring all medical equipment, including a backup cardiac monitor is on site, immediately available for use and functioning properly.
  3. Ensuring that the drugs identified are acquired, arrive at Ely State Prison (ESP) no later than the day of execution and are properly stored. The drugs shall be stored in a secured locked area that is temperature regulated and monitored to ensure compliance with manufacturer specifications, under the direct control of the designated Warden.

## **103.03 PREPARATION OF LETHAL DRUGS**

- A. At the appropriate time, approximately two hours prior to the scheduled execution, the designated Warden shall transfer custody of the drugs to two members of the Security Team who have been selected by the designated Deputy Director as the Drug Administrators. The Drug Administrators will be two individuals who, based upon their years of experience and proven performance within the corrections industry, are uniquely trusted to perform the sensitive and critical tasks of properly preparing the lethal drugs for the execution, and then injecting the lethal drugs into the condemned inmate per these instructions when so ordered.
- B. The quantity of the lethal drugs may not be changed without prior approval of the Director.
- C. It is the responsibility of the Drug Administrators to prepare the lethal drugs. An Attending Physician or other properly trained and qualified medical professional will observe the Drug Administrators as they prepare the lethal drugs.
1. Both Drug Administrators shall complete detailed written reports describing the preparation and labeling of the lethal drugs.
    - a. The Drug Administrators shall be responsible for preparing and labeling the assigned syringes in a distinctive manner identifying the specific lethal drug contained in each syringe by (1) lethal drug name, (2) lethal drug amount and (3) assigned number. This information shall be preprinted on a label, with one label affixed to each syringe to ensure a label remains visible.
    - b. The syringes for each lethal drug by name will then be placed in an individual tray marked for all the syringes of that lethal drug. The labels for each tray and each syringe it contains will be colored to match: red in color for Midazolam, white in color for Fentanyl and blue in color for Cis-atracurium.
    - c. The drugs and their doses are to be prepared and labeled as follows:

i. Tray-1: Midazolam (labels to be red in color)

		<u>DRUG</u>	<u>CONCENTRATION</u>	<u>SYRINGE</u>	<u>TOTAL</u>
1.	#1-1	Midazolam	5mg/cc	10ml	50mg
2.	#1-2	Midazolam	5mg/cc	10ml	50mg
3.	#1-3	Midazolam	5mg/cc	10ml	50mg
4.	#1-4	Midazolam	5mg/cc	10ml	50mg
5.	#1-5	Midazolam	5mg/cc	10ml	50mg
6.	#1-6	Midazolam	5mg/cc	10ml	50mg
7.	#1-7	Midazolam	5mg/cc	10ml	50mg
8.	#1-8	Midazolam	5mg/cc	10ml	50mg
9.	#1-9	Midazolam	5mg/cc	10ml	50mg
10.	#1-10	Midazolam	5mg/cc	10ml	50mg
11.		In the unlikely event that it is deemed necessary (see protocol in EM 110), additional syringes of Midazolam may be ordered by the Director, and then prepared and injected by the Drug Administrators. If ordered, additional syringes will be similarly labeled and numbered next in sequence, for example the next syringe would be numbered #1-11, then #1-12 and so on.			

ii. Tray-2: Fentanyl (labels to be white in color)

		<u>DRUG</u>	<u>CONCENTRATION</u>	<u>SYRINGE</u>	<u>TOTAL</u>
1.	#2-1	Fentanyl	50mcg/cc	10ml	500mcg
2.	#2-2	Fentanyl	50mcg/cc	10ml	500mcg
3.	#2-3	Fentanyl	50mcg/cc	10ml	500mcg
4.	#2-4	Fentanyl	50mcg/cc	10ml	500mcg
5.	#2-5	Fentanyl	50mcg/cc	10ml	500mcg
6.	#2-6	Fentanyl	50mcg/cc	10ml	500mcg
7.	#2-7	Fentanyl	50mcg/cc	10ml	500mcg

- |     |   |          |          |      |        |
|-----|---|----------|----------|------|--------|
| 8.  | #2-8  | Fentanyl | 50mcg/cc | 10ml | 500mcg |
| 9.  | #2-9  | Fentanyl | 50mcg/cc | 10ml | 500mcg |
| 10. | #2-10   | Fentanyl | 50mcg/cc | 10ml | 500mcg |
| 11. | #2-11   | Fentanyl | 50mcg/cc | 10ml | 500mcg |
| 12. | #2-12   | Fentanyl | 50mcg/cc | 10ml | 500mcg |
| 13. | #2-13   | Fentanyl | 50mcg/cc | 10ml | 500mcg |
| 14. | #2-14   | Fentanyl | 50mcg/cc | 10ml | 500mcg |
| 15. | #2-15   | Fentanyl | 50mcg/cc | 10ml | 500mcg |
| 16. | In the unlikely event that it is deemed necessary (see protocol in EM 110), additional syringes of Fentanyl may be ordered by the Director, and then prepared and injected by the Drug Administrators. If ordered, additional syringes will be similarly labeled and numbered next in sequence, for example the next syringe would be numbered #2-16, then #2-17 and so on. |          |          |      |        |

**iii. Tray-3: Cis-atracurium (labels to be blue in color)**


- |     |   | <u>DRUG</u>    | <u>CONCENTRATION</u> | <u>SYRINGE</u> | <u>TOTAL</u> |
|-----|---|----------------|----------------------|----------------|--------------|
| 1.  | #3-1  | Cis-atracurium | 2mg/1ml              | 10ml           | 20mg         |
| 2.  | #3-2  | Cis-atracurium | 2mg/1ml              | 10ml           | 20mg         |
| 3.  | #3-3  | Cis-atracurium | 2mg/1ml              | 10ml           | 20mg         |
| 4.  | #3-4  | Cis-atracurium | 2mg/1ml              | 10ml           | 20mg         |
| 5.  | #3-5  | Cis-atracurium | 2mg/1ml              | 10ml           | 20mg         |
| 6.  | #3-6  | Cis-atracurium | 2mg/1ml              | 10ml           | 20mg         |
| 7.  | #3-7  | Cis-atracurium | 2mg/1ml              | 10ml           | 20mg         |
| 8.  | #3-8  | Cis-atracurium | 2mg/1ml              | 10ml           | 20mg         |
| 9.  | #3-9  | Cis-atracurium | 2mg/1ml              | 10ml           | 20mg         |
| 10. | #3-10   | Cis-atracurium | 2mg/1ml              | 10ml           | 20mg         |
| 11. | In the unlikely event that it is deemed necessary (see protocol in EM 110), additional syringes of Cis-atracurium may be ordered by the Director, and then prepared and injected by the Drug Administrators. If ordered, additional syringes will be similarly labeled and numbered next in |                |                      |                |              |

sequence, for example the next syringe would be numbered #3-11, then #3-12 and so on.

2. One Drug Administrator will prepare and label the lethal drug syringes. The second Drug Administrator will observe, verify the preparation, dosage and labeling of each syringe. The second Drug Administrator will then place the syringes in their correct trays for use.
3. The Drug Administrators shall prepare the designated lethal drugs and syringes so that the correct number of syringes are prepared and placed in each correctly labeled tray.
  - a. To prepare each syringe for use, the Drug Administrator will draw the appropriate amount of supplied drug solution into each syringe so that the specified dose of each drug is made ready in each syringe.
    - i. Midazolam will be used at a concentration of 5 milligrams per milliliter. For this drug, the specified doses to be prepared are 50 milligrams in 10 milliliter syringes. In order to achieve those doses, the Drug Administrator will draw ten (10) milliliters of the supplied solution into each 10 milliliter syringe labeled to contain Midazolam.
    - ii. Fentanyl will be used at a concentration of 50 micrograms per milliliter. For this drug, the specified doses to be prepared are 500 micrograms in each 10 milliliter syringe. In order to achieve those doses, the Drug Administrator will draw ten (10) milliliters of the supplied solution into each 10 milliliter syringe labeled to contain Fentanyl.
    - iii. Cis-atracurium will be used at a concentration of 2 milligrams per milliliter. For this drug, the specified doses to be prepared are 20 milligrams in each 10 milliliter syringe. In order to achieve those doses, the Drug Administrator will draw ten (10) milliliters of the supplied solution into each 10 milliliter syringe labeled to contain Cis-atracurium.

**NO ATTACHMENTS: SEE CEM 112 FOR ALL EXECUTION RELATED FORMS**

0:1 NEVADA DEPT OF CORRECTIONS  
121/140 3955 W. RUSSELL RD-CASA GRANDE  
CENTRAL PHARMACY  
LAS VEGAS, NV 89118-0000



DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	Fee PAID
AS2995922	10-31-2019	Fee EXEMPT
SCHEDULES	BUSINESS ACTIVITY	ISSUE DATE
2,2N, 3,3N,4,5,	HOSPITAL/CLINIC	09-20-2016
NEVADA DEPT OF CORRECTIONS 3955 W. RUSSELL RD-CASA GRANDE CENTRAL PHARMACY LAS VEGAS, NV 89118-0000		

**CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE**  
UNITED STATES DEPARTMENT OF JUSTICE  
DRUG ENFORCEMENT ADMINISTRATION  
WASHINGTON D.C. 20537

Sections 304 and 1008 (21 USC 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

**THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IT IS NOT VALID AFTER THE EXPIRATION DATE.**

<b>CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE</b> UNITED STATES DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WASHINGTON D.C. 20537		
DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	Fee PAID
AS2995922	10-31-2019	Fee EXEMPT
SCHEDULES	BUSINESS ACTIVITY	ISSUE DATE
2,2N, 3,3N,4,5,	HOSPITAL/CLINIC	09-20-2016
NEVADA DEPT OF CORRECTIONS 3955 W. RUSSELL RD-CASA GRANDE CENTRAL PHARMACY LAS VEGAS, NV 89118-0000		

Sections 304 and 1008 (21 USC 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

**THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IT IS NOT VALID AFTER THE EXPIRATION DATE.**

Form DEA-223 (4/07)

NDOC0006



NDC 17478-030-05

**Fentanyl Citrate  
Injection, USP 000  
250 mcg/5 mL  
(50 mcg/mL)**

10 Milliliter Syringe

FOR INTRAVENOUS OR INTRARECTAL USE

C 1

\*Each mL contains:  
Fentanyl base 50 mcg/mL

Rx only

NDOC0008



**Single Dose Vials**

10 x 5 mL Single Dose Vials  
Sterile, Nonpyrogenic

Rx only

Cisatracurium Besylate Injection

000000000000000000000000



TAMPER  
EVIDENT  
TAPE

NET WT 100 mg

Cisatracurium Besylate Injection



TAMPER  
EVIDENT  
TAPE

Rx only

10 x 5 mL Single Dose Vials  
Sterile, Nonpyrogenic

000000000000000000000000



08/2018  
MS704

TAMPER  
EVIDENT  
TAPE

NDOC0010

S

(623) 478-8500



CardinalHealth

CARDINAL HEALTH  
600 N 83RD AVE  
TOLLESON, AZ 85353

PAGE 1 OF 1 ROUTE/STOP 307 / 010

B	DEA RW-0263056	FED ID 68-0158739	CUST. NO.	DATE	ORIGINAL INVOICE
			163264	5/14/18	3768806
			REG NO.	CUST. DEA NO.	ORDER NO.
			CA00001AS2995922	5864116	CUSTOMER P.O. NUMBER
				ORDER DATE	CONF NO.
				5/11/18	07062

S NV DEPT OF CORRECTION CTR PHCY H NV DEPT OF CORRECTION CTR PHCY  
L CENTRAL PHCY I CENTRAL PHCY  
L 3955 W RUSSELL RD-CASA GRANDE P 3955 W RUSSELL RD-CASA GRANDE  
T LAS VEGAS, NV 89118 T LAS VEGAS, NV 89118  
O O

ITEM NUMBER	NDX/UPC	QTY ORDERED	QTY SHIPPED	DESCRIPTION	SIZE	FOR M	RETAIL PRICE	UNIT PRICE	EXTENSION
5392014	47781-0589-91	3	3	CT MIDAZOLAM 5MG/ML 10X1.0ML	C4	10MD 4		17.18	5154CT
	TOTE# 1			PIECES SHIPPED					
		3	3	TOTAL PIECES SHIPPED					
				----- SUMMARRY					
				Total RX			51.54		
				NET AMOUNT			51.54		
INVOICE	SHIP DATE:	5/13/2018							
For SDS	Visit:	<a href="http://www.mycardinalspd.com">http://www.mycardinalspd.com</a>							
PLEASE REMIT YOUR PAYMENTS TO FOLLOWING ADDRESS:									
				CARDINAL HEALTH 110, LLC					
				C/O BANK OF AMERICA					
				PO BOX 56412					
				LOS ANGELES, CA 90074-6412					

PLEASE REMIT YOUR PAYMENTS TO FOLLOWING ADDRESS:

CARDINAL HEALTH 110, LLC

C/O BANK OF AMERICA

PO BOX 56412

LOS ANGELES, CA

90074-6412

For SDS Visit: <http://www.mycardinalspd.com>

PLEASE REMIT YOUR PAYMENTS TO FOLLOWING ADDRESS:

CARDINAL HEALTH 110, LLC

C/O BANK OF AMERICA

PO BOX 56412

LOS ANGELES, CA

90074-6412

Note Codes:	CT Contract	QTY Special Net	7 Drug Recall
T Taxable	Sv Prescriber	4 Nxt stocked	8 New item stock avail
CO Contract Item Override	OV Prescribe	5 Mir Disc	9 Restricted item
SP Special Pricing	CS Source Contract	6 DC Disc	5 Regulatory Review

Customer is a final dispenser purchasing for own use and will not redistribute prescription pharmaceuticals into the secondary market.

Unit Codes:	Dropship	7 Drug Recall
	C Dropship	4 Nxt stocked
	3 Mir Out	5 Mir Disc

The prices shown on this invoice are net of discounts provided at the time of purchase. Some of the products listed on this invoice may be subject to additional discounts or rebates. Please refer to your contract or any specific additional discounts or rebates that may apply to these purchases. You may have an obligation pursuant to 42 USC §1320a-7b to report discounts and rebates to Medicare, Medicaid or other governmental health care programs. Effective January 1, 2015, DSCSA Transaction Data for qualified prescription drugs can be accessed via your usual ordering platform, such as Order Express or Med eCommerce, or at [cardinalhealth.com/trace](http://cardinalhealth.com/trace).

6/13/18  
DUE DATE

5154

6/13/18


DUE DATE

307 / 010

ROUTE/STOP

NDOC0011





NDOC0013



NDOC0014

(623) 478-8500

CARDINAL HEALTH  
600 N 83RD AVE  
TOLLESON, AZ 853

PAGE	1	OF	1	ROUTE/STOP	307	/	010	DV
CUST. NO.		DATE		ORIGINAL INVOICE				
163264		5/23/18		3745130				
REG. NO.	CUST. DEA NO.		ORDER NO.	CUSTOMER P.O. NUMBER				
CA00001AS2995922		5839173	G50218J					
	ORDER DATE		CONF. NO.					
	5/22/18		03152					

**B** S NV DEPT OF CORRECTION CTR PHCY  
L CENTRAL PHCY H NV DEPT OF CORRECTION CTR PHCY  
L 3955 W RUSSELL, RD-CASA GRANDE P CENTRAL PHCY  
L LAS VEGAS, NV 89118 T 3955 W RUSSELL RD-CASA GRANDE  
L LAS VEGAS, NV 89118 R 3955 W RUSSELL RD-CASA GRANDE

**Customer is a final dispenser purchasing for own use and will not redistribute prescription pharmaceuticals into the secondary market**

L13 Chemical Designations  
 E - Ephedrine  
 P - Phenylpropanamine  
 S - Pseudoephedrine  
 C - Other in Chemotherapy

30 / 010

卷之三

The prices shown on this invoice are net of discounts provided at the time of purchase. Some of the products listed on this invoice may be subject to additional discounts or rebates. Please refer to your contract for any specific additional discounts or rebates that may apply to these purchases. You may have an obligation pursuant to 42 USC § 1320e-7b to report discounts and rebates to Medicare, Medicaid or other governmental health care programs.

**Effective January 1, 2015, DSCSA Transaction Data for qualified prescription drugs can be accessed via your usual ordering platform, such as Order Express or Med eCommerce, or at cardinalhealth.com/trace.**

NDOC0015





NDOC0017

S

(623) 478-8500

CARDINAL HEALTH  
600 N 83RD AVE  
TOLLESON, AZ 85353



CardinalHealth

B NV DEPT OF CORRECTION CTR PHCY H NV DEPT OF CORRECTION CTR PHCY  
L CENTRAL PHCY I CENTRAL PHCY  
L 3955 W RUSSELL RD-CASA GRANDE P 3955 W RUSSELL RD-CASA GRANDE  
T LAS VEGAS, NV 89118 T LAS VEGAS, NV 89118  
O 6

DEA RW-0263056 FED ID 68-0158739	CUST. NO.	DATE	ORIGINAL INVOICE
	REG NO.	4/02/18	3667975
	CUST. DEA NO.	ORDER NO.	CUSTOMER P.O. NUMBER
	CA00001AS2995922	5753628	
	ORDER DATE	CONF. NO.	
	3/30/18	06864	

ITEM NUMBER	NDX/UPC	QTY	DESCRIPTION	SIZE	FORM	PRICE	RETAIL PRICE	UNIT PRICE	EXTENSION
3011335   TOTE# 9	00074-4378-05	1	CT NIMBEX 2MG/ML 10X5ML	10ML	10SD			148.23	14823CT
		1	PIECES SHIPPED						
		1	TOTAL PIECES SHIPPED						
			----- S U M M A R Y -----						
			Total RX			148.23			
			NET AMOUNT			148.23			
INVOICE	SHIP DATE:	4/01/2018							
	For SDS Visit:	<a href="http://www.mycardinalsdspd.com">http://www.mycardinalsdspd.com</a>							
	PLEASE REMIT YOUR PAYMENTS TO FOLLOWING ADDRESS:								
			CARDINAL HEALTH 110, LLC						
			C/O BANK OF AMERICA						
			PO BOX 56412						
			LOS ANGELES, CA 90074-6412						

Note Codes: CT Contract Taxable CO Contract Item Owner/Code SP Special Pricing	Omni Codes: CT Contract Sh Special Net Ov Price Override GS Source Contact	7 Drug Recall 8 New ItemStock unavail. 9 Restricted Item S Regulatory Review	1st Chemical Designations: E-Ephedrine P-Phenylpropanamine S-Pseudoephedrine L-Other List Chemical
--	--	---	--

Customer is a final dispenser purchasing for own use and will not redistribute prescription pharmaceuticals into the secondary market.

5/02/18	DUE DATE
---------	----------



14823

5/02/18	DUE DATE
---------	----------



307 / 010

The prices shown on this invoice are net of discounts provided at the time of purchase. Some of the products listed on this invoice may be subject to additional discounts or rebates. Please refer to your contract for any specific additional discounts or rebates that may apply to these purchases. You may have an obligation pursuant to 42 USC § 1320a-7b to report discounts and rebates to Medicare, Medicaid or other governmental health care programs.

Effective January 1, 2015, DSCSA Transaction Data for qualified prescription drugs can be accessed via your usual ordering platform, such as Order Express or Med eCommerce, or at cardinalhealth.com/trace.

NDOC0018



NDOC0019

S

(623) 478-8500



CardinalHealth

CARDINAL HEALTH  
600 N 83RD AVE  
TOLLESON, AZ 85353

DEA RW-0263056 FED ID 68-0158739

B NV DEPT OF CORRECTION CTR PHCY S NV DEPT OF CORRECTION CTR PHCY  
L CENTRAL PHCY I CENTRAL PHCY  
L 3955 W RUSSELL RD-CASA GRANDE P 3955 W RUSSELL RD-CASA GRANDE  
T LAS VEGAS, NV 89118 O LAS VEGAS, NV 89118

		PAGE 1 OF 1		ROUTE/STOP 307 / 010	DV
		CUST. NO. DATE		ORIGINAL INVOICE	
163264		5/14/18		3770403	
REG NO.		CUST. DEA NO.		ORDER NO.	
CA00001AS2995922		5867270		CUSTOMER P.O. NUMBER	
ORDER DATE		CONF. NO.			
5/13/18		08748			

ITEM NUMBER	NDX/UPC	QTY ORDERED	QTY SHIPPED	DESCRIPTION	SIZE	FORM	RETAIL PRICE	UNIT PRICE	EXTENSION
5316179	00074-4382-20	1	1	NIMBEX 10MG/ML 10X20ML	10SL			2810.32	281032CT
	TOTE# 11			PIECES SHIPPED					
			1	TOTAL PIECES SHIPPED					
				Total RX			2810.32		
				NET AMOUNT			2810.32		
INVOICE	SHIP DATE:	5/13/2018							
For SDS	Visit:	<a href="http://www.mycardinalspd.com">http://www.mycardinalspd.com</a>							
PLEASE REMIT YOUR PAYMENTS TO FOLLOWING ADDRESS:									
				CARDINAL HEALTH 110, LLC					
				C/O BANK OF AMERICA					
				PO BOX 56412					
				LOS ANGELES, CA 90074-6412					

INVOICE

SHIP DATE:

5/13/2018

For SDS Visit: <http://www.mycardinalspd.com>

PLEASE REMIT YOUR PAYMENTS TO FOLLOWING ADDRESS:

CARDINAL HEALTH 110, LLC

C/O BANK OF AMERICA

PO BOX 56412

LOS ANGELES, CA 90074-6412

Note Codes:	CT Contract	CRN Codes:	7 Drug Recall
T Taxable	SN Special Net	C Drosophia	4 Not stocked
CO Contract Item Override	OV Price Override	2 DC Cut	3 New item stock unavail
SP Special Pricing	CS Source Contract	5 Mfr Cut	9 Recycled Item
		3 Mfr Out	S Regulatory Review
		5 DC Disc	
		3 Mfr Out	

Unit Chemical Designations
E-Ephedrine
P-Pseudoephedrine
S-S
L-Other Lit Chemical

6/13/18	DUE DATE
---------	----------



Customer is a final dispenser purchasing for own use and will not redistribute prescription pharmaceuticals into the secondary market.

The prices shown on this invoice are net of discounts provided at the time of purchase. Some of the products listed on this invoice may be subject to additional discounts or rebates. Please refer to your contract for any specific additional discounts or rebates that may apply to these purchases. You may have an obligation pursuant to 42 USC § 1320a-7b to report discounts and rebates to Medicare, Medicaid or other governmental health care programs. Effective January 1, 2015, DSCSA Transaction Data for qualified prescription drugs can be accessed via your usual ordering platform, such as Order Express or Med eCommerce, or at [cardinalhealth.com/trace](http://cardinalhealth.com/trace).

NDOC0020

**Nimbex®**  
Cisatracurium  
Besylate Injection  
**200 mg/20 mL**  
(10 mg/mL)  
Single-dose vial

**Nimbex®**  
Cisatracurium  
Besylate Injection  
**200 mg/20 mL**  
(10 mg/mL)  
Single-dose vial

**Nimbex®**  
Cisatracurium  
Besylate Injection  
**200 mg/20 mL**  
(10 mg/mL)  
Single-dose vial

**Nimbex®**  
Cisatracurium  
Besylate Injection  
**200 mg/20 mL**  
(10 mg/mL)  
Single-dose vial

**Nimbex®**  
Cisatracurium  
Besylate injection  
**200 mg/20 mL**  
(10 mg/mL)  
Single-dose vial

**Nimbex®**  
Cisatracurium  
Besylate Injection  
**200 mg/20 mL**  
(10 mg/mL)  
Single-dose vial

**Nimbex®**  
Cisatracurium  
Besylate Injection  
**200 mg/20 mL**  
(10 mg/mL)  
Single-dose vial

**Nimbex®**  
Cisatracurium  
Besylate Injection  
**200 mg/20 mL**  
(10 mg/mL)  
Single-dose vial

**Nimbex®**  
Cisatracurium  
Besylate Injection  
**200 mg/20 mL**  
(10 mg/mL)  
Single-dose vial

**Nimbex®**  
Cisatracurium  
Besylate Injecti  
**200 mg/20 mL**  
(10 mg/mL)  
Single-dose via

NDC 0074-4382-20

NDC 0074-4382-20

NDC 0074-4382-20

NDC 0074-4382-20

NDC 0074-43

Nimbex®

Nimbex®

Nimbex®

Nimbex®

Nimbex®

TAMF  
EVADI  
TAT

LINE  
EER

NDOC0021